Ohio State Navbar


More About Dr. Abdel-Rahman

Staff photo

400 W Twelfth Ave
Rm 252N Wiseman Hall
Columbus, OH 43210

Phone: (614) 292-1396

Email: abdel-rahman.4@osu.edu


Current OSU Appointment

Assistant Professor, Ophthalmology



Spending one third of my life and more than one half of my adult life at The Ohio State University made me a true “Buckeye” and it gives me a great pride to be an Associate Professor in the Department of Ophthalmology and Visual Science at OSU.

After finishing medical school, pathology residency and fellowship training in Egypt I came to OSU in the fall of 1997 to pursue my graduate education which I finished in 2002 with a PhD in Pathology. After a short post-doc at UTMDACC I came back to OSU for another post-doc at the department of ophthalmology then a clinical fellowship in cancer genetics. I went back to Egypt in 2006 where I worked as attending pathologist at the National Liver Institute, Menoufiya University then I was recruited back to OSU in 2009. Since then, I have been on the faculty of the department of ophthalmology and as an adjunct faculty at the division of human genetics. In late 2011 I lost my late wife in a tragic accident. I also suffered physical injuries. This tragedy impacted my productivity significantly. I also had to take time off to care for my children and to heal. Upon returning I was able to resume my research projects and successfully compete for NIH support.

Since I came to OSU as a faculty I believe that I exhibited sustained evidence of excellence in the discovery and dissemination of new knowledge and demonstrated national and international level of significance and recognition of scholarship to warrant my promotion to Associate Professor. The following are some of my accomplishments:

A. Scholarship:

I. Research on BAP1-Tumor Predisposition Syndrome (TPDS):

- In 2011 we were one of three independent research groups to characterize a novel hereditary cancer predisposition syndrome caused by germline mutation in the BAP1 gene (OMIM # 614327). This new hereditary cancer syndrome is associated with multiple different cancers including uveal melanoma, cutaneous melanoma, mesothelioma, atypical Spitz nevi, renal cell carcinoma and potentially other cancers.

- Our manuscript was the first to describe the multi-cancer aspect of the BAP1-TPDS. It has been selected as the JMG editors’ choice and it made publicly available. Since its publication in 2011 it has been cited 183. The article is cited by OMIM as one of the four references describing the BAP1-TPDS. In addition, we published several follow up manuscripts expanding the clinical phenotype of the syndrome and describing the proposed clinical management. They are also well cited.

- We prepared a clinical guideline for diagnosis and management of the BAP1-TPDS syndrome for the NCBI online resource GeneReviews. Our manuscript has been accepted for publication and will appear online next week. As described on their website “Genereviews is an international point-of-care resource for clinicians that provide clinically relevant and medically actionable information for inherited conditions. It covers diagnosis, management, and genetic counseling for patients and their families. It currently has 669 chapters. Each chapter is written by one or more experts on the specific condition or disease and goes through a rigorous editing and peer review process”.

- Our expertise at OSU in BAP1 is well recognized nationally and internationally. So far I have been invited to review four international grants on BAP1, I completed 3 and declined one for lack of time and reviewed 8 manuscripts on BAP1 (including journals such as New England J of Medicine, Nature review cancer and PLOS genetics). I have been invited to give one local, two national and three international guest lectures on the topic. My co-worker Robert Pilarski has been invited as a plenary speaker on the BAP1-TPDS at the National Genetic Counselor Society meeting and he was also invited to give genetic counselor education lectures at NIH and NCI on the syndrome. My co-worker Colleen Cebulla has been invited to give talks on the topic to the retinal society.

- Based on our well recognized expertise in BAP1 and hereditary predisposition to uveal melanoma we have received patients' referral from 27 different states in the US with a 44% accrual from outside OSU. We also received patients’ referral and consultation requests from several foreign countries including Italy, Canada, Belgium, UK, Ireland, Australia, Brazil, Netherlands and Jordan. In addition, many patients from outside Ohio travel to our program for counseling and guidance.

- We are currently leading the effort to establish an international registry for BAP1-TPDS patients and we developed a redcap database questionnaire.

- Our expertise in BAP1 sequencing is also well recognized, we are a referral research laboratory for patients with clinical features suggestive of the syndrome. Also I have received several requests from academic and clinical laboratories to assist and troubleshoot the development of their sequencing assays.

II. Research on Hereditary Predisposition to Uveal Melanoma:

- We have changed the very limited view of hereditary predisposition to uveal melanoma from being a rare familial cancer (less than1% of all patients), to a more common 12% of uveal melanoma population with a heterogeneous cancer phenotype.

- Based on our strong national and international reputation we accrued 32 familial uveal melanoma patients/families (there are only 115 patients reported worldwide). This was well recognized by the reviewers of my funded R21 NCI grant who noted that our patient cohort is one of the largest for familial uveal melanoma collected in the World. In addition, we accrued more than 150 uveal melanoma patients with strong personal and family history of cancers. This includes 20 patients referred to our program by Cleveland Clinic. These large familial uveal melanoma and high-risk hereditary cancer cohorts are the foundation for a multi-PI R01 grant that we submitted to the NCI recently.

- I built a multi-institutional consortium that includes OSU, Cleveland Clinic and Liverpool Ocular Oncology Group. The later is the third largest ocular oncology referral program in Europe. This multi-institutional consortium that has already accrued >1200 uveal melanoma patients an accrual goal of >1000 additional patients in 3 years was instrumental in our recent multi-PI NCI R01 grant submission.

- Our NCI funded R21 award helped with the characterization of additional hereditary cancer predisposition genes. I’ll be presenting one of these genes ATAD5 in the upcoming American Society of Human Genetic Meeting and I submitted an NCI R03 grant to further study that gene in uveal melanoma.

- We recently identified variants in pigmentary gene HERC2 that control eye color—as risk alleles for uveal melanoma. The discovery has been recognized in multiple media outlet and in ASCO and PLOS communications. This discovery provide a paradigm shift in the field since uveal melanoma is not linked to UV exposure suggesting additional molecular mechanisms for its carcinogenics role. This discovery is the basis of a pelotonia grant that we recently submitted and to an upcoming NCI R21 that we are planning to submit in response to the NCI provocative questions.

III. Research on Somatic Genetic Alterations in Uveal Melanoma

- I served as co-investigator for the NIH Cancer Genome Atlas (TCGA) Project for uveal melanoma (UM). The well annotated biorepository that we developed was one of 6 centers in the world to contribute uveal melanoma tissues and matching normal samples to the TCGA.

- I was member of the Pathology Expert panel, the Analysis and Writing Groups for the TCGA. I played a critical role in the reanalysis of BAP1 gene alterations and contributed to writing the UM-TCGA marker paper which has been submitted to Cancer Cell.

- I am serving as co-investigator for multicenter adjuvant clinical trial for high-risk uveal melanoma (grants.gov NCT02223819, OSU 14129 Olencki (PI) “Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy”). The trial has opened September, 2016. One of my papers (MET oncogene inhibition as a potential target of therapy for uveal melanomas, IOVS 2010: 51,7: 3333-9) provided important preliminary data for this trial.

IV. Research on Ocular and Tumor Angiogenesis and anti-angiogenic agents

- We had two published manuscripts on anti-angiogenic agents and an ongoing project to study anti-angiogenic agents from natural product. The later is funded by an award from the Ohio Lions Eye Research Foundation.

- Based on my expertise in angiogenesis studies I'll serve as a co-Investigator on an NCI R01 grant on the Deciphering the non-pigmentary phenotypic impacts of OCA2 variants.

V. Research on Hepatocellular Carcinoma

- This is part of my global outreach effort to address one of the growing cancer problems in my native country Egypt and also in the US.

- As part of healing process after my tragedy in 2011, I lead the efforts to establish a biorepository and research laboratory at National Liver Institute, Menoufiya University. The political turmoil in the country, slowed our progress significantly but we were able to have the project up and running in 2013.

- During the last 1.5 years they have been able to accrue a large cohort of HCC patients and controls including more than 1200 serum/plasma/DNA samples from HCC patients. This cohort is the basis of a recent collaborative US/Egyptian grant that we submitted to the USAID. Also through utilizing this resources I collaborated with Dr. Christopher Cross from College of pharmacy, OSU to submit a Pelotonia grant to study HCC and I am working with him on an upcoming R21 NCI grant submission.

- I have been active member of the OSU liver Cancer research interest group and we are currently developing IRB approved retrospective and prospective biorepositories for patients with HCC from OSU.

- Our preliminary work on HCC has been recently selected as a top score poster at the International Liver Cancer Association meeting in 2016.

B. Teaching and Mentoring:

- Since the start of my faculty appointment at OSU in 2009 I mentored seven undergraduate students Benjamin Christopher, Omar Saqr, Samidha Dutta, Tiffany Wang, Karan Rai and Timothy Grosel. I also mentored the summer research projects of three medical students Benjamin Romney, Kareem Saleh and Muneeb Rehman. Currently I am mentoring one undergraduate student Khara Walker who is funded through a Pelotonia award.

- I am on the advising committee of several graduate students from Egypt. Two of my graduate students (Ahmad Agour and Asmaa Abdel-Maksood) obtained scholarships and came to OSU for part of their training. I currently have a doctorate degree student Laila Farid on a 1-year joint supervision program funded through the Egypt Mission Department.

- At OSU I taught pathology and genetics to ophthalmology residents and graduate students in Genetic Counseling Master Program.

- As part of global outreach and education I gave several seminars and workshops on genetics, molecular genetics at the Menoufiya University and Children Cancer Hospital in Egypt.

- I’ll be teaching molecular genetics to pathology residents and fellow in Egypt as part of education training program for the UK membership of royal college of pathologists’ examination (MRCPath).

C. Service:

- Director ocular oncology research laboratory, department of ophthalmology, OSU (01/2011-present).

- Director of ophthalmic pathology education for ophthalmology residents (2012)

- Member of medical retina fellowship selection committee (2014-present)

- Founder and Director of National Liver Institute, Sustainable Sciences Institute Collaborative Research Laboratory (NLISSICRC) Egypt (09/2011-08/2012). Obtained a $100,000 grant from the SSI to establish a biorepository and research laboratory. Carried out training (in Egypt and at OSU) for young researcher and established a biorepository.

- Scientific advisor and consultant of NLISSICRC, Egypt. (09/2012-present). Maintained fund and supervised scientific progress of the center.

- Grants reviewer for: Research Counsels UK, British Lung Foundation UK and North West Cancer Research, Liverpool, UK.

- Ad-hoc reviewer for: Cancer Research, Molecular Cancer Therapy, Clinical Cancer Research, Investigative Ophthalmology and Visual Science, British Journal of Cancer, Melanoma Research, British Journal of Ophthalmology, Nature Reviews Cancer, PLOS one, PLOS genetics and New England Journal of Medicine.

- Scientific advisor for Egyptian Student Association at the OSU (2014-2015).

- TCGA project: member of the Analysis Working Group, Pathology Expert Group and Manuscript writing group (2014-2016)

- Non compensated spoke person for American Cancer Society and Melanoma Know More Foundations

- Course Director: Havener Eye Institute 57th Annual Post graduate Symposium in Ophthalmology, The Ohio State University, Columbus, Ohio, United States (2014).

Clinical Interest

Anatomic Pathology

Clinical Medical Genetics

Academic Advising

I am a strong believer of investing in undergraduate students' research especially for highly talented candidates. My strategy is to select one or two students/year who I train and give independent research projects. I try to limit the number of students rotating in the lab at any time to maximum of two students so I can have sufficient time for mentoring. Although working with undergraduate students is challenging I find it highly rewarding.

In addition to the long term projects carried out by selected undergraduate students I accept other undergraduate and medical students for shorter rotations depending on their expertise and research interests. .

Since the start of my faculty appointment at OSU in 2009 I mentored four undergraduate students Benjamin Christopher, Omar Saqr, Samidha Dutta, Tiffany Wang, Karan Rai and Timothy Grosel . I also mentored three medical students research projects Benjamin Romney, Kareem Saleh and Muneeb Rehman. Currently I am mentoring one undergraduate student Khara Walker who is funded through a Pelotonia award.

I have been on the advising committee of several graduate students in Egypt. Two of my graduate students from Egypt (Ahmad Agour and Asmaa Abdel-Maksood) obtained scholarships and came to OSU for part of their training. I currently have a doctorate degree student Laila Farid on joint supervision program funded through the Egypt Mission Department.

Noteworthy Graduate Narrative

The doctorate candidate student Eman Adbelsamee, MD is currently a junior faculty (lecturer) at Menoufiya University.

Samira Abdelwehab. MD is currently a junior faculty at pediatric hepatology program Menoufiya University.

Master/Graduate Advising

I currently mentor 5 PhD students from Egypt (1 from Menoufiya University, 1 from Cairo University, 1 from An Shams University and 2 from Sadat University.

Two of them Ahmed A. Agour, MD, MSc and Asmaa Mosbah, MSc obtained scholarships and came to my laboratory at OSU for 3 months to carry out part of their training.

One of them Laila Farid is currently in my lab on a Doctorate Joint-Supervision Scholarship funded through the Egyptian Mission Department (1-2 yrs based on available funds).

Continuing Education, Extension, and Other Courses Taught

I’ll be teaching molecular genetics to pathology residents and fellows in Egypt as part of education training program for the UK membership of royal college of pathologists’ examination (MRCPath). I have been selected by the organizing committee for my expertise in the field. This will be an annual training program.

I also carried out workshops at several universities in Egypt on the basics of genetics, molecular genetics and cell biology.

Academic Advising

2014 Thomas Grosel, The Ohio State University. Graduated 2016.
2015 Laila Magid, Ain Shams University. Graduated 0.
2016 Khara Waler, The Ohio State University. Graduated 0.
2013 Omar Saqr, The Ohio State University. Graduated 2013. Study of germline BAP1 and VHL mutation in uveal melanoma patients with personal and or family history of renal cell carcinoma
2014 Muneeb Rehman, The Ohio State University. Graduated 0. Study of a Novel Candidate Gene for Hereditary Predisposition to Uveal Melanoma
2014 Kareem Saleh, The Ohio State University. Molecular Genetics of Choroidal Nevi
2013 - 2015 Elaine M, The Ohio State University. Graduated 2015. Analysis of BAP1 germline gene mutation in young uveal melanoma patients
2014 - 2015 Karan Rai, The Ohio State University. Graduated 2015. Comprehensive Review of BAP1 Tumor Predisposition Syndrome
2015 - 2016 Karan Rai, The Ohio State University. Graduated 0.


1992 - present Unrestricted Medical License: Egyptian Ministry of Health
1992 - present General Medical Practitioner: Egyptian Ministry of Health
1998 - present ECFMG: Educational Commission for Foreign Medical Graduates
2007 - present Histopathology Consultant: Egyptian Ministry of Health
2007 - present Consultant Histopathology: Egyptian Medical Syndicate
2009 - present Unrestricted Medical License: State Medical Board of Ohio

Clinical Services

07/01/2007 Pathology Practice (Menoufiya, Egypt)


Yang,Y; Meadows,S; Li,P,K; Davidorf,F,H; Abdel-Rahman,M,H. "Anti-angiogenic effect of Linomide analogue." In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. (January 2005). 4166-.

Abdel-Rahman MH, Hedges D, Pilarski R, Boru G, Massengill JB, Rai K, Davidorf FH, Cebulla CM. "Whole genome exome sequencing to identify novel candidates for hereditary predisposition to UM uveal melanoma.." In abstracts.ashg.org. (October 2014). 2014: 3484T-.

Pilarski R, Boru G, Saqr OH, Rai K, Massengill JB, Cebulla CM, Abdel-Rahman MH.. "Germline epigenetic inactivation of BAP1 in a subset of patients with uveal melanoma.." In abstracts.ashg.org. (October 2014). 2014: 3485T-.

Cebulla CM, Pilarski R, Rai K, Massengill JB, Boru G, Davidorf FH, Abdel-Rahman MH.. "Two novel germline BAP1 mutations in two unrelated families with features of the BAP1 Tumor Predisposition Syndrome.." In abstracts.ashg.org. (October 2014). 2014: 3485S-.

Kim B, Kusibati R, Binkley E, Abdel-Rahman MH, Cebulla CM.. "Up-Regulation of VEGF by Hyaluronic Acid in Microglia." In ARVO meetinabstracts. (April 2014). 2014 55:2261-.

Binkley EM, Cebulla CM, Pilarski R, Massengill JB, Marino MJ, Singh AD, Abdel-Rahman MH.. "Lack of BAP1 germline gene mutation in patients with early onset uveal melanoma." In ARVO meeting abstracts. (April 2014). 2014 55:5077-.

Abdel-Rahman, MH, Rai, K, Pilarski, R, Davidorf, F, Cebulla, C,M.. "Germline BAP1 mutations misreported as somatic based on tumor-only testing.." In ASHG online abstracts. (October 2015). PgmNr 2767-.

Kirchhoff, T, Ucisik-Akkaya, E, Vogelsang, M, Martinez, C,N, Rai, K,, Pilarski, R, Ferguson, R, Rendleman, J, Kazlow, E, Osman, I, Davidorf, F,H, Cebulla, C,M, Abdel-Rahman, M,H.. "The identification of novel genetic risk loci in uveal melanoma.." In J. Clin Oncol. (June 2016). suppl, abstr 1543-.



1990 M.D., Cairo University

1996 M.S., Menoufiya University

2002 Ph.D., The Ohio State University


Editorial Activities

present Familial Cancer
present Dove Medical Publications
present Clinical Cancer Research
present Cancer Research
2009 - present Investigatve Ophthalmology and Visual Sciences
2012 - present Nature Review Cancer
2016 - present British Jounral of Ophthalmology


2000 - present Loes Jones Endowment for cancer research fellowship award. Comprehensive Cancer Center.
2001 - present Travel Fellowship. 10th International Congress of Human Genetics.
2010 - present Junior Investigator Award. Ocular Melanoma Foundation.

Journal Articles

Abdel-Rahman,M,H; Craig,E,L; Davidorf,F,H; Eng,C. "Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number." CLINICAL CANCER RESEARCH. Vol. 11, no. 1. (January 2005.): 73-78.

Abdel-Rahman,M,H; Yang,Y; Zhou,X,P; Craig,E,L; Davidorf,F,H; Eng,C. "High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma." JOURNAL OF CLINICAL ONCOLOGY. Vol. 24, no. 2. (January 2006.): 288-295.

Abbas,Omaima,M; Abdel-Rahman,Mohamed,H; Omar,Nabil,A; Badran,Hanaa,M; Amir,Elamir,M. "Interleukin-10 promoter polymorphisms in hepatitis C patients with and without Schistosoma mansoni co-infection." LIVER INTERNATIONAL. Vol. 29, no. 9. (October 2009.): 1422-1430.

Abdel-Rahman,M,H; Pilarski,R; Ezzat,S; Sexton,J; Davidorf,F,H. "Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma." FAMILIAL CANCER. Vol. 9, no. 3. (September 2010.): 431-438.

Abdel-Rahman,M,H; Yang,Y; Salem,M,M; Meadows,S; Massengill,James,B; Li,P-K; Davidorf,F,H. "Investigation of the potential utility of a linomide analogue for treatment of choroidal neovascularization." EXPERIMENTAL EYE RESEARCH. Vol. 91, no. 6. (December 2010.): 837-843.

Abdel-Rahman,Mohamed,H; Pilarski,Robert; Cebulla,Colleen,M; Massengill,James,B; Christopher,Benjamin,N; Boru,Getachew; Hovland,Peter; Davidorf,Frederick,H. "Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers." JOURNAL OF MEDICAL GENETICS. Vol. 48, no. 12. (December 2011.): 856-859.

Abdel-Rahman,Mohamed,H; Pilarski,Robert; Massengill,James,B; Christopher,Benjamin,B; Davidorf,Frederick,H. "Lack of GNAQ germline mutations in uveal melanoma patients with high risk for hereditary cancer predisposition." FAMILIAL CANCER. Vol. 10, no. 2. (June 2011.): 319-321.

Christopher,Benjamin,N; Cebulla,Colleen,M; Wakely,Paul,E; Davidoff,Frederick,H; Abdel-Rahman,Mohamed,H. "Molecular genetic testing of uveal melanoma from routinely processed and stained cytology specimens." EXPERIMENTAL EYE RESEARCH. Vol. 93, no. 5. (November 2011.): 720-725.

Salem,Manar,M; Davidorf,Frederick,H; Abdel-Rahman,Mohamed,H. "In vitro anti-uveal melanoma activity of phenolic compounds from the Egyptian medicinal plant Acacia nilotica." FITOTERAPIA. Vol. 82, no. 8. (December 2011.): 1279-1284.

Abdel-Rahman,Mohamed,H; Cebulla,Colleen,M; Verma,Vishal; Christopher,Benjamin,N; Carson,William,E; Olencki,Thomas; Davidorf,Frederick,H. "Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival." EXPERIMENTAL EYE RESEARCH. Vol. 100, (July 2012.): 26-31.

Abdel-Rahman MH, Agour AA and El-Azab DS. "Tissue microarray as a research tool to study non-eoplastic liver diseases." Egyptian Liver Journal. Vol. 4, no. 3. (July 2014.): 69-74.

Martorano,Lisa,M; Winkelmann,Richard,R; Cebulla,Colleen,M; Abdel-Rahman,Mohamed,H; Campbell,Shannon,M. "Overview of uveal melanoma." INTERNATIONAL JOURNAL OF DERMATOLOGY. Vol. 53, no. 6. (June 2014.): 657-663.

Pilarski,Robert; Cebulla,Colleen,M; Massengill,James,B; Rai,Karan; Rich,Thereasa; Strong,Louise; McGillivray,Barbara; Asrat,Mary-Jill; Davidorf,Frederick,H; Abdel-Rahman,Mohamed,H. "Expanding the Clinical Phenotype of Hereditary BAP1 Cancer Predisposition Syndrome, Reporting Three New Cases." GENES CHROMOSOMES & CANCER. Vol. 53, no. 2. (February 2014.): 177-182.

Kim,Bongsu; Abdel-Rahman,Mohamed,H; Wang,Tiffany; Pouly,Severin; Mahmoud,Ashraf,M; Cebulla,Colleen,M. "Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 Expression in Murine Experimental Retinal Detachment." INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. Vol. 55, no. 4. (April 2014.): 2031-2040.

Abdel-Rahman,Mohamed,H; Rai,Karan; Pilarski,Robert; Davidorf,Frederick,H; Cebulla,Colleen,M. "Germline BAP1 mutations misreported as somatic based on tumor-only testing." FAMILIAL CANCER. Vol. 15, no. 2. (April 2016.): 327-330.

Rai,K; Pilarski,R; Cebulla,C,M; Abdel-Rahman,M,H. "Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases." CLINICAL GENETICS. Vol. 89, no. 3. (March 2016.): 285-294.



"The Practice of Clinical Cancer Genetics." Presented at 1St International Scientific Conference, Children’s Cancer Hospital, Egypt, Cairo, EG|EGY. (July 2009)

"Hereditary predisposition to uveal melanoma." Presented at Great Lake Ocular Oncology Seminar, . (October 2012)

"Lessons learned from the genetics of a rare eye tumor." Presented at Biology Seminar Series, American University Cairo, Cairo, EG|EGY. (September 2014)

"Clinical cancer genetics; ophthalmology perspective." Presented at OSU postgraduate course in Ophthalmolgy, Columbus, OH, US|USA. (February 2014)

"Advances in Genetics and Pathology of Uveal Melanoma." Presented at 1st Middle East Conference in Ophthalmic Oncology, Cairo, EG|EGY. (December 2016)


Professional Activities

present Denman Undergraduate research forum 2012. The Ohio State University.
present Denman Undergraduate research forum 2015. The Ohio State University.
present Denman Undergraduate research forum 2016. The Ohio State University.
present Denman Undergraduate research forum 2014. The Ohio State University.
- 2009 Denman Undergraduate Research Forum. The Ohio State University.
- 2010 OSUMC research day. College of Medicine, The Ohio State University.
- 2010 Denman Undergraduate research forum. The Ohio State University.
- 2010 Invited speaker. Children's Cancer Hospital of Egypt.
- 2010 Educational workshop. Children's Cancer Hospital of Egypt.
- 2011 OSUMC research day 2011. College of Medicine, The Ohio State University.
- 2011 Denman Undergadutae Research Forum 2011. The Ohio State University.
- 2011 Non compensated spokesperson. American Cancer Society.
- 2011 OSUMC research day 2013. College of Medicine, The Ohio State University.
2011 - 2012 Establishing a bio-repository research laboratory and program in molecular genetics in Egypt. Sustainable Sciences Institute & Menoufiya University.
2015 Tumor Cancer Genome Atlas Uveal Melanoma. Pathology Expert Panel. National Cancer Institute.
2014 - 2016 Tumor Cancer Genome Atlas Uveal Melanoma Analysis Working Group. National Cancer Institute.

Unpublished Works

Boru, G, Cebulla, CM, Olencki T, Carson W III, Davidorf, FH, Abdel-Rahman, MH.. Heterogeneity in MAPK activation and GNAQ and GNA11 somatic mutations in uveal melanomas, potential impact for therapy. January 0.